Drugs / Amolimogene
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00264732 | Jul 2005 → May 2009 | dysplasia of cervix | Eisai Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amolimogene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00264732 ↗ |
| Route | Intramuscular | “Two intramuscular (IM) injections (100 micrograms ZYC101a per injection)” NCT00264732 ↗ |